CVS Outperforms on Strong Fundamentals, but Regulatory and Litigation Risks Persist

What happened

CVS Health's stock has outperformed the market in 2026, driven by a string of better-than-expected profitability results that have reinforced Wall Street's bullishness, with some analysts projecting another 22% upside. The company's fundamentals have strengthened as management executed on its enterprise-wide restructuring, targeting over $500 million in cost savings for 2025, while raising adjusted EPS guidance to $6.30-$6.40, and recent quarterly results showed improved margins in the Health Care Benefits segment despite one-time litigation charges. The market's positive reaction reflects growing confidence that the Medicare utilization spike that pressured 2024 earnings is stabilizing, and that strategic shifts toward transparent pricing models like TrueCost and CostVantage are gaining traction with clients. However, the stock's recent run-up means it now trades closer to fair value, and significant risks remain, including potential negative outcomes from ongoing PBM regulatory scrutiny and the possibility of further litigation charges that could disrupt earnings. While the fundamental turnaround appears genuine, investors should temper enthusiasm until the company demonstrates sustained profitability improvements over consecutive quarters.

Implication

For long-term investors, CVS's integrated model and cost-saving initiatives provide a solid foundation for continued earnings growth, but the current valuation suggests that much of the good news is already priced in. The company's ability to navigate PBM regulatory challenges and avoid additional litigation will be critical to maintaining momentum. Investors should closely monitor Medicare utilization trends, client retention under new pricing models, and the execution of restructuring goals before adding to positions. While the analyst price targets indicate upside, a more conservative stance may be warranted until risks are more fully resolved. Overall, CVS remains a BUY for patient investors, but the margin of safety has narrowed.

Thesis delta

Previous analysis rated CVS a BUY based on its low ~12x P/E and improving fundamentals. The recent stock outperformance and analyst optimism suggest the market is finally recognizing those strengths, reducing the valuation discount. However, the core thesis remains intact; we maintain a BUY stance with the caveat that the entry point is less attractive now than it was earlier in the year.